Baillie Gifford & Co. Invests $15.53 Million in Revolution Medicines, Inc. $RVMD

Baillie Gifford & Co. purchased a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 194,959 shares of the company’s stock, valued at approximately $15,528,000. Baillie Gifford & Co. owned 0.10% of Revolution Medicines as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Signaturefd LLC grew its stake in Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after purchasing an additional 163 shares in the last quarter. GAMMA Investing LLC grew its stake in Revolution Medicines by 45.1% in the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Revolution Medicines by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company’s stock worth $2,528,000 after purchasing an additional 336 shares in the last quarter. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines in the fourth quarter worth approximately $32,000. Finally, California State Teachers Retirement System grew its stake in Revolution Medicines by 0.3% in the second quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock worth $5,153,000 after purchasing an additional 437 shares in the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Stock Up 41.3%

Shares of NASDAQ RVMD opened at $136.30 on Tuesday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $27.01 billion, a PE ratio of -23.06 and a beta of 1.01. The stock’s fifty day simple moving average is $98.90 and its two-hundred day simple moving average is $83.55. Revolution Medicines, Inc. has a 12-month low of $34.00 and a 12-month high of $136.80.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter last year, the company earned ($1.12) earnings per share. As a group, analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on RVMD shares. Evercore raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Truist Financial raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Jefferies Financial Group started coverage on Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating on the stock. UBS Group started coverage on Revolution Medicines in a research note on Friday, February 27th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $78.94.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares of the company’s stock, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Jack Anders sold 2,753 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $273,868.44. Following the sale, the chief financial officer directly owned 125,512 shares in the company, valued at $12,485,933.76. This trade represents a 2.15% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 64,592 shares of company stock worth $6,488,732. 8.20% of the stock is currently owned by company insiders.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Late-stage trial win — Revolution reported positive Phase 3 results for daraxonrasib in pancreatic cancer, showing substantially longer survival and a ~60% reduction in risk of death versus chemotherapy; this is being framed as a potential breakthrough for a hard-to-treat indication and prompted a surge in the stock. Reuters: Experimental cancer pill helps improve survival
• Positive Sentiment: Broad media and analyst attention — Major outlets (CNBC, Barron’s, others) highlighted the trial success and the stock’s rally; at least one boutique analyst (LifeSci Capital) reiterated a buy stance recently, adding to investor enthusiasm. CNBC: Pancreatic cancer drug succeeds
• Neutral Sentiment: High trading and option activity — Volume spiked well above average and there were reports of heavy put option flows ahead of and during the move; this reflects elevated speculative and hedging activity but is ambiguous for direction beyond today’s momentum. Article on put option activity
• Neutral Sentiment: Clinical program context — The company previously announced and has been advancing the RASolute 303 Phase 3 program (daraxonrasib) as first-line treatment for metastatic pancreatic cancer; the new result is from a late-stage readout that materially changes prospects compared with earlier-stage updates. Globe and Mail: RASolute 303 trial begins
• Negative Sentiment: Planned equity and debt offerings — The company announced proposed public offerings of $750M of common stock and $250M of convertible senior notes (plus underwriter options). That raise, if completed, would be dilutive and could cap near-term upside even as clinical results improve long-term fundamentals. Globe Newswire: Proposed offerings announced

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.